Key Points - Group sales increased by 6.5% in constant currency, marking the sixth consecutive quarter of sales growth, with customer demand remaining stable compared to Q2 [2] - Sales growth is driven by innovation, particularly in Beauty Actives, with continued strength in Fragrance & Flavors (F&F) and a recovery in Crop [2] - The company will optimize utilization at shared production sites through targeted sales in Beauty Care, Crop, and Industrial Specialties as part of ongoing actions since 2024 [3]

Growth through innovation is the only way to keep living standards rising (via @opinion) https://t.co/tUYYev16Dv ...

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [6][7][16] - Adjusted earnings per share of $1.30 was in line with consensus estimates, and foreign exchange had a favorable year-over-year impact of 1.4% on third quarter sales [16][17] - Adjusted gross margin was 55.8% of sales, reflecting a decrease due to tariffs, while adjusted operating margin increased by 40 basis points to 23% of sales [16][17] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in adult nutrition products like Ensure and Glucerna [8][9] - Diagnostics saw modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China, while point-of-care diagnostics grew by 8% [9][10] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets, with strong contributions from therapeutic areas like gastroenterology and cardiometabolic [10][11] - Medical devices experienced a 12.5% sales growth, driven by double-digit growth in diabetes care and cardiac rhythm management [11][12] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while Europe saw growth of 6% to 7%, and Latin America grew in the mid-teens [46][47] - In China, the company faced headwinds from VBP pricing dynamics, but growth in other segments like EPD and nutrition remained strong, with overall growth in China around 5% to 7% when excluding diagnostics [65][66] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and easing headwinds from diagnostics [20][25] - Investments in innovation and a robust pipeline are expected to drive future growth, with nearly 200 clinical trials planned for next year [24][25] - The company is focused on expanding its market share in key segments, including diabetes care and cardiac rhythm management, with new product launches like Volt and dual analyte sensors [22][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and new product launches as key growth drivers [20][21] - The company anticipates a recovery in the diagnostics business as headwinds from China moderate and new products are rolled out [48] - Management highlighted the importance of addressing barriers to CGM penetration in the basal segment and emphasized ongoing efforts to increase awareness among primary care physicians [78][80] Other Important Information - Recent product launches contributed nearly half a billion dollars in sales this quarter, adding over 100 basis points to organic sales growth [8] - The company is advancing its biosimilars strategy, with several regulatory approvals expected in the near future [10] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting continued growth driven by product momentum and easing headwinds [20] Question: U.S. diabetes growth dynamics - U.S. diabetes care grew 19%, with expectations for strong growth next year driven by new product launches [29][32] Question: Diagnostics business headwinds - Management acknowledged challenges in the diagnostics segment due to VBP in China but expects a recovery as these headwinds moderate [44][48] Question: Cardiac rhythm management growth - The cardiac rhythm management segment is experiencing significant growth, with expectations for continued market share gains [67][69] Question: Structural heart market outlook - Management is optimistic about the structural heart market, particularly with upcoming product launches and competitive advancements [75][76]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [6][7][16] - Adjusted gross margin was 55.8% of sales, showing a decrease from the prior year due to tariffs, while adjusted operating margin increased by 40 basis points to 23% of sales [16][52] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in the adult nutrition segment [8][9] - Diagnostics experienced modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China [9][10] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets [10] - Medical devices saw a 12.5% sales growth, with significant contributions from diabetes care and electrophysiology [11][12] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while Europe saw growth of 6% to 7%, and Latin America experienced mid-teens growth [46] - In China, the company faced challenges due to VBP pricing dynamics, but growth in other segments remained stable, with a projected growth rate of 5% to 7% excluding diagnostics [65][66] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and a strong existing portfolio [20][25] - Investments in innovation and clinical trials are expected to drive future growth, with nearly 200 clinical trials planned for next year [24][25] - The company is focused on expanding its market share in key segments, including diabetes care and cardiac rhythm management [68][69] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [20][21] - The company anticipates a recovery in the diagnostics business, particularly outside of China, and expects to see improved performance in 2026 [48][66] Other Important Information - Recent product launches contributed nearly half a billion dollars in sales this quarter, enhancing organic sales growth [8] - The company is advancing its biosimilars strategy, with several regulatory approvals expected in the near future [10] Q&A Session Summary Question: Thoughts on next year's sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting continued growth driven by product momentum and easing headwinds [20][21] Question: Insights on diabetes growth in the U.S. and internationally - U.S. diabetes care grew 19%, with expectations for strong growth next year driven by new product launches [29][31] Question: Updates on the diagnostics business and recovery expectations - Management noted that while challenges remain in China, the diagnostics business outside of China is expected to accelerate, with a recovery anticipated next year [46][48] Question: Performance of the electrophysiology franchise - The electrophysiology segment is experiencing double-digit growth, with positive feedback on new products like the Volt catheter [35][36] Question: Outlook for the cardiac rhythm management market - The dual chamber leadless pacemaker market is expected to grow significantly, with current penetration rates indicating substantial room for growth [68][69] Question: Update on structural heart and left atrial appendage closure - Management is optimistic about future growth in left atrial appendage closure, with new product trials expected to yield positive results [74][75]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [5][13] - Adjusted gross margin was 55.8% of sales, showing a decrease from the prior year due to tariffs, while adjusted operating margin increased by 40 basis points to 23% [14][48] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in adult nutrition products like Ensure and Glucerna [6][7] - Diagnostics experienced modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China, while point-of-care diagnostics grew by 8% [7][8] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets, with strong contributions from therapeutic areas like gastroenterology and cardiometabolic [8][9] - Medical devices saw a 12.5% sales growth, with significant contributions from diabetes care and electrophysiology [9][10] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while the European region saw growth of 6% to 7%, and Latin America grew in the mid-teens [44] - In China, the company faced challenges due to VBP pricing dynamics, but growth in other segments like EPD and nutrition remained strong, with an overall growth rate of around 5% to 7% when excluding diagnostics [61][62] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and a strong existing portfolio [21][22] - Investments in innovation and clinical trials are expected to drive future growth, with nearly 200 clinical trials planned across various businesses [21][23] - The company is focused on expanding its market share in key areas such as diabetes care and electrophysiology, with new product launches like Volt expected to enhance growth [19][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [18][19] - The company anticipates a recovery in the diagnostics business as it laps previous headwinds, with expectations for mid-to-high single-digit growth next year [45] - Management highlighted the importance of adapting to market conditions and maintaining a resilient portfolio to drive growth [19][23] Other Important Information - The company has launched new products that generated nearly half a billion dollars in sales this quarter, contributing significantly to organic sales growth [6] - Regulatory approvals for new medical devices, such as Triclip in Japan and expanded indications for TAVR, are expected to enhance market position [10][11] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting to deliver similar growth rates as in 2025 despite headwinds faced this year [18] Question: Insights on U.S. diabetes market growth - U.S. diabetes care grew by 19%, with expectations for continued strong growth driven by new product launches and increased penetration in the basal segment [26][28] Question: Drivers of ablation catheter growth - Double-digit growth in ablation catheters is driven significantly by international markets, with a strong competitive position in mapping cases [52][53] Question: Outlook for diagnostics business in China - Management expects mid-single-digit growth in China, focusing on expanding contributions from other geographies while navigating current challenges [62] Question: Update on nutrition litigation and market performance - The company remains committed to defending its products amid ongoing litigation, with pockets of softness in nutrition being addressed through strategic investments [80]

Nominations are now open for Forbes CIO Next 2025. Submit a leader who is driving innovation, transformation, and impact through technology.Learn more: https://t.co/ZEElQff1Uw ...

China has about 4x as many people as the United States, yet the US continues to hold its own on the global stage.That is the power of capitalism, democracy, and a culture of innovation. ...

Core Insights - Cooper Standard's Industrial & Specialty Group (ISG) will be featured on the television series Inside the Blueprint, highlighting its innovative solutions across various industries [1][2][3] Group 1: Company Overview - Cooper Standard is a leading global supplier of sealing and fluid handling systems, with a presence in 20 countries and approximately 22,000 team members [5] - The ISG focuses on accelerating growth in non-automotive and specialty markets, leveraging significant investments in technology and innovation [5] Group 2: Media Feature - The Inside the Blueprint segment will air on FOX Business on October 18 at 3 p.m. ET and on Bloomberg on October 19 at 4 p.m. ET, reaching millions of viewers [2] - The segment will showcase ISG's approach to developing customized solutions that enhance performance and efficiency in various applications, including transportation, HVAC, and agriculture [3][4] Group 3: Innovation and Growth - ISG emphasizes its commitment to innovation and sustainability, with plans to participate in industry trade shows like Glassbuild America and AHR Expo [4] - The feature on Inside the Blueprint reflects ISG's collaborative spirit and its role in shaping the future of industries through high-performance solutions [4]

🎉 A decade of trust, growth, and innovation 🌍From our first trade in 2015 to serving users in 160+ countries, LBank has come a long way.💎 No.1 in 100x Gems🔥 No.1 in Meme Share🔐 10 years with zero security incidentsThank you to over 20 million users who made this journey possible.Here’s to the next chapter.#LBank10Years #LBank10thAnniversary ...